IL324673A - Compounds and formulations useful as vaccine adjuvants - Google Patents

Compounds and formulations useful as vaccine adjuvants

Info

Publication number
IL324673A
IL324673A IL324673A IL32467325A IL324673A IL 324673 A IL324673 A IL 324673A IL 324673 A IL324673 A IL 324673A IL 32467325 A IL32467325 A IL 32467325A IL 324673 A IL324673 A IL 324673A
Authority
IL
Israel
Prior art keywords
compounds
vaccine adjuvants
formulations useful
formulations
useful
Prior art date
Application number
IL324673A
Other languages
Hebrew (he)
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of IL324673A publication Critical patent/IL324673A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL324673A 2023-05-18 2025-11-16 Compounds and formulations useful as vaccine adjuvants IL324673A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363503015P 2023-05-18 2023-05-18
PCT/US2024/029596 WO2024238735A1 (en) 2023-05-18 2024-05-16 Compounds and formulations useful as vaccine adjuvants

Publications (1)

Publication Number Publication Date
IL324673A true IL324673A (en) 2026-01-01

Family

ID=93520078

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324673A IL324673A (en) 2023-05-18 2025-11-16 Compounds and formulations useful as vaccine adjuvants

Country Status (5)

Country Link
AU (1) AU2024270736A1 (en)
CO (1) CO2025016120A2 (en)
IL (1) IL324673A (en)
MX (1) MX2025013689A (en)
WO (1) WO2024238735A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111249B2 (en) * 2017-05-18 2021-09-07 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl-pyrazole derivative, and preparation method therefor and medical application thereof
US11554120B2 (en) * 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2021247809A1 (en) * 2020-06-04 2021-12-09 Merck Sharp & Dohme Corp. PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS

Also Published As

Publication number Publication date
WO2024238735A1 (en) 2024-11-21
MX2025013689A (en) 2025-12-01
AU2024270736A1 (en) 2025-12-18
CO2025016120A2 (en) 2025-12-09

Similar Documents

Publication Publication Date Title
GB202212336D0 (en) Coronavirus vaccine formulations
EP4135762A4 (en) Large sequence pan-coronavirus vaccine compositions
IL306088A (en) Coronavirus vaccine formulations
EP4321020A4 (en) Oral vaccine composition
IL286254A (en) tlr4 and tlr7 ligand formulations as vaccine adjuvants
EP4146204A4 (en) VACCINE ADJUVANTS
IL324673A (en) Compounds and formulations useful as vaccine adjuvants
CA3292453A1 (en) Compounds and formulations useful as vaccine adjuvants
IL321069A (en) Pneumococcal conjugate vaccine formulations
GB202205231D0 (en) Vaccine compositions
SG11202108896UA (en) Vaccine adjuvants and formulations
GB202207281D0 (en) Vaccine
GB202107170D0 (en) Vaccine compositions
GB202013262D0 (en) Vaccine Composition
GB202317903D0 (en) Vaccine formulation
HK40065844A (en) Vaccine adjuvants and formulations
HK40083308A (en) Vaccine formulations
IL320790A (en) Low dose vaccine compositions
CA3291532A1 (en) Vaccine adjuvants
GB202314361D0 (en) Vaccine compositions and uses thereof
AU2025905871A0 (en) Vaccine adjuvants
HK40117626A (en) Coronavirus vaccine formulations
HK40105934A (en) Coronavirus vaccine formulations
HK40075990A (en) Coronavirus vaccine formulations
GB202502815D0 (en) Vaccine